Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-12-05
2006-12-05
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C546S048000, C548S131000, C549S323000, C549S510000
Reexamination Certificate
active
07144876
ABSTRACT:
Disclosed are 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I:wherein Ar1, R2, A, B and D are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
REFERENCES:
patent: 3772441 (1973-11-01), Lombardino
patent: 3879404 (1975-04-01), Baldwin et al.
patent: 4791124 (1988-12-01), Lutomski et al.
patent: 5134142 (1992-07-01), Matsuo et al.
patent: 5464848 (1995-11-01), Diana et al.
patent: 6121260 (2000-09-01), Thurkauf et al.
patent: 6277873 (2001-08-01), Yu et al.
patent: 2003/0045546 (2003-03-01), Cai et al.
patent: WO 96/20721 (1996-07-01), None
patent: WO 02/100826 (2002-12-01), None
Caplus Abstract 135:46140.
Caplus 118:101879.
Ca 124:343192.
Caplus Abstract 135:46140, “An improved synthesis of 1,2,4-oxadiazoles on sold support”, Rice et al., Bioorganic & Medicinal Chemistry Letters (2001), 11(6), 753-755.
Caplus 118:101879, “Antihydatic agent: synthesis of 3-substituted phenyl-5-substituted-1,2,4-oxadiazles”, Gao et. al.
D'Andrea et. al., “Docetaxel and Paclitaxel in Breast Cancer Therapy: Present Status and Future Prospects”, Seminars in Oncology, vol. 24, No. 4, Suppl 13 (Aug.), 1997: pp. S13-27-S13-44.
Rice et. al., “An Improved Synthesis of 1,2, 4-Oxadiazoles on Solid Support”, Bioorganic & Medicinal Chemistry Letters 11 (2001) 753-755.
Iino, M., et al., “Rational Design and Evaluation of New Lead Compound Structures for Selective βARK1 Inhibitors,”J. Med. Chem. 45:2150-2159, American Chemical Society (2002).
International Search Report for PCT Patent Application No. PCT/US03/40308, mailed May 19, 2004, Alexandria, VA.
Batteux, F., et al., “Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand,”J. Immunol. 162:603-608, The American Association of Immunologists (1999).
Boirivant, M., et al., “Lamina Propria T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis,”Gastroenterology 116:557-565, The American Gastroenterological Association (1999).
Chinnaiyan, A.M., et al., “The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication,”Nat. Med. 3:333-337, Nature Publishing Co. (1997).
Coven, T.R., et al., “PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis,”Photodermatol. Photoimmunol. Photomed. 15:22-27, Munksgaard (1999).
Ellis, R.E., et al., “Mechanisms and Functions of Cell Death,”Ann. Rev. Cell Biol. 7:663-698, Annual Reviews, Inc. (1991).
Friesen, C., et al., “Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells,”Nat. Med. 2:574-577, Nature Publishing Co. (1996).
Greenwald, R.B., “Drug Delivery Systems Employing 1,4- or 1,6-Elimination: Poly(ethylene glycol) Prodrugs of Amine-Containing Compounds,”J. Med. Chem. 42:3657-3667, American Chemical Society (1999).
Heenen, M., et al., “Methotrexate induces apoptotic cell death in human keratinocytes,”Arch. Dermatol. Res. 290:240-245, Springer-Verlag (1998).
Infante, A.J., et al., “The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis,”J. Pediatr. 133:629-633, Mosby, Inc. (1998).
Leu, Y.-L., et al., “Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT),”J. Med. Chem. 42:3623-3628, American Chemical Society (1999).
López-Hoyos, M., et al., “Regulation of B cell apoptosis by Bcl-2 and Bcl-XLand its role in the development of autoimmune diseases (Review),”Int. J. Mol. Med. 1:475-483, D.A. Spandidos (1998).
Los, M., et al., “Cross-Resistance of CD95- and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases),”Blood 90:3118-3129, W.B. Saunders Co. (1997).
O'Reilly, L.A., and Strasser, A., “Apoptosis and autoimmune disease,”Inflamm. Res. 48:5-21, Birkhäuser Verlag (1999).
Ohsako, S., and Elkon, K.B., “Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis,”Cell Death Differ. 6:13-21, Stockton Press (1999).
Orrenius, S., “Apoptosis: molecular mechanisms and implications for human disease,”J. Internal Med. 237:529-536, Blackwell Science Ltd. (1995).
Ozawa, M., et al., “312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions,”J. Exp. Med. 189:711-718, The Rockefeller University Press (1999).
Savill, J., “Apoptosis in resolution of inflammation,”J. Leukoc. Biol. 61:375-380, The Society for Leukocyte Biology (1997).
Schmitt, E., et al., “The Bcl-xL and BAX-α control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation,”Biochem. Cell Biol. 75:301-314, National Research Council of Canada (1997).
Tai, D.-I., et al., “Activation of Nuclear Factor kB in Hepatitis C Virus Infection: Implications for Pathogenesis and Hepatocarcinogenesis,”Hepatology 3:656-664, W.B. Saunders Co. (Mar. 2000).
Thornberry, N.A., “The caspase family of cysteine proteases,”Brit. Med. Bull. 53:478-490, Oxford University Press (1997).
Thornberry, N.A., “Caspases: key mediators of apoptosis,”Chem. Biol. 5:R97-R103, Current Biology Ltd. (1998).
Vaishnaw, A.K., et al., “The molecular basis for apoptotic defects in patients with CD95 (FAS/Apo-1) mutations,”J. Clin. Invest. 103:355-363, The American Society for Clinical Investigation (1999).
Wakisaka, S., et al., “Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA),”Clin. Exp. Immunol. 114:119-128, Blackwell Science (1998).
Wyllie, A.H., et al., “Cell Death: The Significance of Apoptosis,”Int. Rev. Cyt. 68:251-306, Academic Press, Inc. (1980).
Wyllie, A.H., “Cell death: a new classification separating apoptosis from necrosis,” inCell death in biology and pathology, Bowen and Lockshin, eds., Chapman and Hall, London, England, pp. 9-34 (1981).
Zhou, T., et al., “Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases,”Nat. Med. 5:42-48, Nature Publishing Co. (1999).
Cai Sui Xiong
Kemnitzer William E
Kuemmerle Jared D
Zhang Han-Zhong
Zhang Hong
Chung Susannah L.
Cytovia, Inc.
McKane Joseph K.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3719715